<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Caitlin S Latimer, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas J Montine, MD, PHD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3161559121"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dementia with Lewy bodies (DLB) is one of the most common causes of dementia after Alzheimer disease (AD) and vascular dementia. DLB often presents a diagnostic challenge given this clinical heterogeneity and overlap with other neurodegenerative diseases. Further, it was initially often overlooked pathologically because of the difficulty in identifying cortical Lewy bodies with routine histochemical stains. With the advent of immunohistochemical stains for constituents of Lewy bodies, the prevalence of this disorder has been better characterized. However, challenges still remain in defining and diagnosing DLB as an entity distinct from other degenerative dementias.</p><p>DLB has been given various names over the years, which in part reflects the uncertainty as to whether it is one of several distinct disease entities with the shared common finding of cortical Lewy bodies, or represents one point on a spectrum of Lewy body disease. Names by which it has been called include diffuse Lewy body disease, Lewy body dementia, Lewy body variant of AD, cortical Lewy body disease, and senile dementia of the Lewy body type. More recently there has been an effort to apply the term "Lewy body disease" as a collective description of the various entities characterized pathologically by Lewy body formation (Parkinson disease [PD], PD dementia [PDD], and DLB), the terms "diffuse Lewy body disease" and "neocortical Lewy body disease" to describe the finding of Lewy bodies in neocortical neurons, and the term "DLB" to describe the clinical syndrome.</p><p>This topic will describe the epidemiology, neuropathologic findings, and potential pathogenic mechanisms of DLB. Clinical features, diagnosis, prognosis, and treatment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies"</a> and  <a class="medical medical_review" href="/z/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies"</a>.)</p><p class="headingAnchor" id="H4246660743"><span class="h1">INCIDENCE AND PREVALENCE</span><span class="headingEndMark"> — </span>DLB, although once considered rare, is recognized as a common cause of neurodegenerative dementia, affecting up to 5 percent of the general population and accounting for as much as 30 percent of all dementia cases [<a href="#rid1">1,2</a>]. Such prevalence estimates place DLB as one of the most common causes of dementia, superseded only by Alzheimer disease (AD) and vascular dementia. Incidence rates have been estimated at 0.1 percent per year in the general population but up to 3.2 percent for new dementia cases [<a href="#rid1">1</a>].</p><p>Similar to other neurodegenerative diseases, the prevalence of DLB increases with age [<a href="#rid3">3</a>], with an average age at presentation of 75 years [<a href="#rid4">4</a>]. DLB has been reported to occur more frequently in males, with a male-to-female ratio of 4:1 [<a href="#rid5">5</a>]. However, a separate study showed an increased prevalence of Lewy body pathology in females compared with males [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H22134380"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H412738885"><span class="h2">Gross pathology</span><span class="headingEndMark"> — </span>DLB is associated with nonspecific gross pathologic changes of the brain that overlap with other neurodegenerative diseases such as Alzheimer disease (AD) and Parkinson disease (PD) [<a href="#rid7">7</a>]. The cortical atrophy is typically less marked than AD but follows a similar pattern, involving frontal, temporal, and parietal lobes, with relative sparing of occipital cortex. Limbic structures, such as the amygdala and cingulate gyrus, however, can show severe atrophy. Similar to PD, the substantia nigra and the locus coeruleus can show variable degrees of pallor.</p><p class="headingAnchor" id="H794262145"><span class="h2">Microscopic pathology</span><span class="headingEndMark"> — </span>The microscopic pathologic hallmark of DLB is the presence of Lewy bodies throughout the neocortex as well as in the brainstem nuclei and limbic structures [<a href="#rid8">8,9</a>]. On hematoxylin- and eosin-stained sections, these round, eosinophilic, cytoplasmic inclusions can be seen readily in pigmented neurons within the substantia nigra and locus coeruleus but are less easily visualized in cortical neurons [<a href="#rid10">10</a>]. Immunohistochemical staining for alpha-synuclein [<a href="#rid10">10</a>], as well as p62 (a protein of the nuclear envelope that colocalizes with ubiquitin-tagged proteins) and ubiquitin [<a href="#rid11">11</a>], can aid in the identification of Lewy bodies, particularly outside the brainstem nuclei  (<a class="graphic graphic_picture graphicRef119653 graphicRef119654" href="/z/d/graphic/119653.html" rel="external">picture 1A-B</a>). Cerebral cortical Lewy bodies are often localized to small neurons in the deep cortical layers and typically involve the temporal cortex, followed by the parietal and frontal cortex.</p><p>In addition to Lewy bodies, Lewy neurites are also visualized with the aid of alpha-synuclein immunohistochemistry [<a href="#rid10">10</a>]. These elongate, beaded nerve processes are found in the CA2 and CA3 regions of the hippocampus, the transentorhinal cortex, the nucleus basalis of Meynert, amygdala, dorsal vagal nucleus, and other brainstem nuclei. </p><p>Superficial microvacuolation of cerebral cortex, especially temporal cortex, is another feature noted in some cases and may be related to disease severity [<a href="#rid12">12</a>].</p><p>Up to 80 percent of patients with DLB will have concomitant AD neuropathologic change [<a href="#rid13">13-15</a>]. Often the AD changes are less severe than in cases of AD dementia without Lewy bodies, particularly with respect to the extent of neurofibrillary degeneration [<a href="#rid16">16</a>]. AD pathology is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16575.html" rel="external">"Epidemiology, pathology, and pathogenesis of Alzheimer disease", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H2824305583"><span class="h1">CLINICOPATHOLOGIC CORRELATION</span><span class="headingEndMark"> — </span>A number of studies have attempted to characterize the relationship between Lewy body quantity or distribution and symptoms, and this has generally proven to be challenging.</p><p>In one pathologic series, the overall density of Lewy bodies correlated with the severity of cognitive impairment, independent of other neuropathologic changes [<a href="#rid17">17</a>]. However, in another series, individuals with pure DLB had only moderate cognitive impairment, regardless of the extent of neocortical Lewy bodies [<a href="#rid18">18</a>].</p><p>Others have demonstrated an association between the localization and density of Lewy bodies with other clinical symptoms, such as visual hallucinations with increased numbers of Lewy bodies in the anterior and inferior temporal lobe [<a href="#rid19">19</a>], as well as dysautonomic symptoms with Lewy bodies in the spinal cord intermediolateral cell column, hypothalamus, and dorsal vagal nuclei [<a href="#rid4">4,20</a>]. However, a robust relationship between Lewy bodies and the fluctuating cognition characteristic of DLB has not been demonstrated. In some cases, Lewy neurites and neurotransmitter deficits appear to associate better with some of the clinical symptoms than Lewy bodies [<a href="#rid21">21,22</a>]. Others have observed that, compared with controls, there is marked loss of dopaminergic neurons in the periaqueductal gray area of the midbrain in DLB, which is thought to correlate with the observation that some patients with DLB have excessive daytime sleepiness [<a href="#rid23">23</a>].</p><p>The presence of concomitant Alzheimer disease (AD) neuropathologic change is thought to modify the clinical presentation and makes such cases difficult to differentiate clinically [<a href="#rid24">24</a>]. For example, some studies have shown that the presence of high-stage neurofibrillary degeneration is associated with a clinical presentation more similar to AD with increased severity of cognitive impairment and older age at presentation [<a href="#rid25">25,26</a>]. However, other studies suggest that the degree of AD and Lewy body pathologic changes are independent of one another and that both are independently associated with severity and duration of dementia [<a href="#rid27">27</a>].</p><p>There is significant overlap and convergence of the clinical presentation of DLB and Parkinson disease dementia (PDD), which are distinguished primarily by the temporal sequence of clinical characteristics [<a href="#rid28">28</a>]. Similarly, the neuropathologic features of DLB and PDD are similar, including Lewy bodies in cortical, limbic, and subcortical brainstem regions. Although there are some distinguishing trends in the neuropathologic features of DLB and PDD, including increased prevalence and extent of concomitant AD neuropathologic changes in DLB and differences in Lewy body distribution and severity, both are highly variable and it is unreliable to attempt to distinguish one from the other on pathologic features alone. The clinical features of DLB and PDD are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/5089.html" rel="external">"Cognitive impairment and dementia in Parkinson disease"</a> and  <a class="medical medical_review" href="/z/d/html/5089.html" rel="external">"Cognitive impairment and dementia in Parkinson disease", section on 'Clinical features'</a>.)</p><p>There are also cases in which neocortical Lewy bodies are identified but there is no clinical history of dementia. This apparent resilience to the presence of Lewy bodies is poorly understood but may represent a preclinical phase of Lewy body disease [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1106002330"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-synuclein</strong> – Aggregated alpha-synuclein is a key component of Lewy bodies and Lewy neurites [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">Alpha-synuclein is expressed throughout the brain and is localized at presynaptic terminals [<a href="#rid31">31,32</a>]. Its function is not entirely understood but is believed to play a role in neurotransmitter release and vesicle turnover [<a href="#rid33">33</a>]. Under pathologic conditions, such as elevated oxidative stress, alpha-synuclein undergoes a structural change from its natively unfolded state to form oligomers and protofibrils, and ultimately beta sheet structures that organize and deposit as Lewy bodies [<a href="#rid8">8,33</a>]. It is not known whether Lewy bodies and Lewy neurites are themselves neurotoxic, whether they are bystanders in the disease process, or whether they represent an attempt to limit injury from the neurotoxic alpha-synuclein oligomers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell type susceptibility and dysfunction</strong> – Dopaminergic neurons appear to be more susceptible to alpha-synuclein dysfunction and Lewy body formation, which may be due to the fact that these neurons have a greater need for alpha-synuclein [<a href="#rid34">34</a>]. There is evidence that alpha-synuclein may play a role in dopamine metabolism by modulating the activity of tyrosine hydroxylase and reducing its ability to hydroxylate tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) [<a href="#rid35">35</a>]. Alpha-synuclein may also regulate the activity of the dopamine transporter (DAT), reducing the reuptake of dopamine back into dopaminergic nerve terminals [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">There is also significant cholinergic neuronal loss and severely depleted choline acetyltransferase (ChAT) levels early in DLB [<a href="#rid37">37,38</a>]. Reduced cortical levels of ChAT have been associated with the presence of hallucinations [<a href="#rid37">37-39</a>]. In two patients, marked reduction in ChAT activity identified postmortem appeared to correlate with a clinical response to cholinesterase inhibitors during life [<a href="#rid37">37</a>]. Thus, cholinergic depletion appears to be an important factor in the symptoms of early DLB, at least in some patients. Increased density of postsynaptic muscarinic acetylcholine receptors has also been reported in DLB and associated with delusions [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regional susceptibility and spread</strong> – Lewy body disease has been staged based on the apparent order of progression, beginning with the lower brainstem or olfactory bulb, spreading rostrally to the substantia nigra, then into the limbic areas, and finally involving the neocortex [<a href="#rid41">41</a>]. There is some evidence that alpha-synuclein propagates trans-synaptically to contribute to the anatomic spread of Lewy bodies [<a href="#rid42">42,43</a>]. This theory is supported by in vitro and in vivo studies that demonstrate the endocytosis of extracellular oligomeric aggregates as well as the transmembrane translocation of monomeric alpha-synuclein [<a href="#rid44">44-46</a>]. Additionally, studies from patients with Lewy body disease who received healthy embryonic neuron grafts have revealed that approximately five years post-transplant, neurons within the graft developed Lewy bodies [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Animal and cell models</strong> – There are a number of mouse models for Parkinson disease (PD), and motor deficits have been better studied than cognitive deficits in these models of alpha-synuclein overexpression [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent1">However, there are some rodent models that produce reliable cognitive deficits and can provide end-point measures to test new therapies for DLB [<a href="#rid51">51</a>]. Similar to DLB in humans, these models show predominantly cerebral cortical and hippocampal Lewy body formation with associated deficits in hippocampal function.</p><p></p><p class="bulletIndent1">In addition to animal models, there are several different cellular models that are increasingly being used to study DLB and other synucleinopathies. Seeding primary neuron cultures with alpha-synuclein fibrils is a model that recapitulates many of the key structural and biochemical features of Lewy body pathogenesis [<a href="#rid52">52</a>]. Point mutations can also be genetically engineered into human pluripotent stem cells to help understand the temporal and cell-type specific regulation of alpha-synuclein and ultimately to screen for potential therapeutic targets [<a href="#rid53">53,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic targets</strong> – There are currently no disease-modifying therapies for DLB, but there are several agents currently in clinical trials [<a href="#rid55">55</a>]. While previous therapeutic targets were focused on symptomatic relief, disease-modifying therapies have more recently been under investigation.</p><p></p><p class="bulletIndent1">Given the human, animal, and cell model data implicating alpha-synuclein aggregation in the manifestation and progression of DLB, therapeutic strategies have focused on reducing alpha-synuclein levels in the brain [<a href="#rid56">56</a>]. These include immunization with antibodies that recognize abnormal alpha-synuclein and promote its degradation, alpha-synuclein gene knockdown with viral vector-based RNA interference strategies, and small molecule and peptide inhibitors of alpha-synuclein. These strategies are still experimental, and at present, the only treatment options for patients are those aimed at symptom relief by increasing dopaminergic and cholinergic neurotransmission. (See  <a class="medical medical_review" href="/z/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H1273354792"><span class="h1">PREDISPOSING FACTORS</span></p><p class="headingAnchor" id="H3965913709"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Although DLB is considered to be mostly a sporadic, late-onset disease, there have been a number of DLB families described in the literature. In addition, a DLB genome-wide association study (GWAS) has provided evidence that genetic factors play an important role in the pathogenesis of both familial and sporadic forms of DLB, accounting for up to 60 percent of disease susceptibility [<a href="#rid57">57,58</a>]. </p><p>Mutations in some genes appear to play a causal role in DLB pathogenesis while others modulate disease risk. Importantly, the genes implicated in DLB have also been associated with other neurodegenerative diseases [<a href="#rid59">59</a>], as described below, while genes specific to DLB have yet to be identified [<a href="#rid60">60</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>SNCA</em></strong>: The gene encoding the alpha-synuclein protein has been implicated in both Parkinson disease (PD) and DLB [<a href="#rid61">61</a>]. Several point mutations have been identified but are relatively rare and result in a diverse phenotypic spectrum ranging from PD, to PD dementia (PDD), to DLB as well as multiple system atrophy (MSA) and frontotemporal dementia (FTD). Even within families there is a wide variety of disease expression, and some mutations are not fully penetrant. The role of mutations in this gene is not clear, but some appear to increase the propensity for aggregation of the alpha-synuclein protein while others may perturb its membrane-binding ability. Mutations in the other members of the synuclein family (beta-synuclein and gamma-synuclein) have also been identified and may play a role in the processes that lead to DLB [<a href="#rid62">62</a>]. <em>SNCA</em> in PD and MSA is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4906.html" rel="external">"Epidemiology, pathogenesis, and genetics of Parkinson disease", section on 'SNCA-associated PD'</a> and  <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">"Multiple system atrophy: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>APP</em></strong>: Mutations in the amyloid precursor protein gene have long been associated with Alzheimer disease (AD) and have more recently been linked to DLB. For example, duplication of <em>APP </em>was reported in a family with autopsy-confirmed DLB [<a href="#rid63">63</a>], and to date, 53 percent of autopsies performed on individuals with the <em>APP</em>717 mutation have revealed the presence of Lewy bodies, suggesting a direct link between <em>APP </em>and Lewy body formation [<a href="#rid64">64,65</a>]. The role of amyloid precursor protein gene in AD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Amyloid precursor protein'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>PSEN1/PSEN2</em></strong>: Point mutations in the presenilin genes are another example of important causes of familial AD that also have been linked to DLB. Presenilins are key components of the gamma-secretase complex involved in the processing of amyloid, and it has been hypothesized that these mutations, which result in increased levels of beta-amyloid, may provide an environment conducive to Lewy body formation [<a href="#rid66">66</a>]. Specifically, the p.DT440 point mutation in <em>PSEN1</em>, which has been reported in a patient with combined clinical and pathologic features of DLB/AD [<a href="#rid67">67</a>], has been shown to enhance Ser129 phosphorylation of alpha-synuclein [<a href="#rid68">68</a>]. The role of presenilins in AD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Presenilin 1'</a> and  <a class="medical medical_review" href="/z/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Presenilin 2'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MAPT</em></strong>: Mutations in the microtubule-associated protein tau gene are associated with tauopathies such as FTD, but more recently, mutations in this gene have been linked to the pathologic changes of DLB and may play a role in promoting the aggregation of alpha-synuclein [<a href="#rid69">69</a>]. The role of this gene in FTD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'MAPT mutations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>GBA</em></strong>: Homozygous mutations in the glucocerebrosidase gene cause Gaucher disease. The observation that some patients with Gaucher disease also had parkinsonian features led to studies showing that heterozygous variants in <em>GBA </em>can predispose to PD and DLB [<a href="#rid70">70-72</a>] (see  <a class="medical medical_review" href="/z/d/html/2918.html" rel="external">"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Genetics'</a>). Mutations in <em>GBA </em>result in reduced activity of beta-glucocerebrosidase, a lysosomal enzyme, which has been shown to impair degradation of alpha-synuclein within the lysosome, leading to its accumulation [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1">The reported frequency of <em>GBA </em>mutations ranges from 4 to 28 percent in cohorts of patients with DLB [<a href="#rid71">71,74</a>]. The frequency was even higher (31 percent) in a study of patients with DLB who were of Ashkenazi descent, a population with a high carrier rate of <em>GBA</em> mutations [<a href="#rid75">75</a>]. In this population, the presence of a <em>GBA </em>mutation was associated with earlier disease onset (64 versus 69 years), as well as more severe motor and cognitive impairment, but similar median survival from the time of diagnosis (10.5 versus 9.2 years). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>APOE</em></strong>: Similar to AD, the apolipoprotein E epsilon 4<em> </em>(ε4) allele has been associated with increased risk of DLB, and the <em>APOE </em>ε2 allele with decreased risk of DLB [<a href="#rid76">76-78</a>]. (See  <a class="medical medical_review" href="/z/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Apolipoprotein E'</a>.)</p><p></p><p class="bulletIndent1">In a cohort that included 667 pathologically confirmed DLB cases and 2624 controls, <em>APOE </em>was confirmed as a strong risk factor for DLB [<a href="#rid79">79</a>]. This association remains even in the absence of AD, suggesting that <em>APOE </em>is related to DLB in a manner unrelated to the amyloid cascade.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>CNTN1</em></strong>:<em> </em>One genome-wide association study in DLB provided evidence of a novel candidate locus, contactin 1 (<em>CNTN1</em>; rs7314908) [<a href="#rid57">57</a>]. <em>CNTN1</em> encodes for the contactin 1 protein, a neuronal membrane protein that functions as a cell-adhesion molecule with a role in axonal function [<a href="#rid80">80,81</a>]. </p><p></p><p class="headingAnchor" id="H3784742176"><span class="h2">Acquired risk factors</span><span class="headingEndMark"> — </span>Although genetic factors are an important component of DLB, the incidence of DLB is generally discordant among monozygotic twins [<a href="#rid82">82</a>], evidence that environmental or other epigenetic factors play an important role in the pathogenesis of DLB. While this has been extensively evaluated in PD, and a number of associations have been made, the same findings have not yet been reported in DLB, which may in part reflect the previous underrepresentation of DLB. One study in community-based cohorts found that traumatic brain injury with loss of consciousness is associated with neocortical Lewy bodies in addition to PD and parkinsonism [<a href="#rid83">83</a>]. Risk factors in PD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4906.html" rel="external">"Epidemiology, pathogenesis, and genetics of Parkinson disease"</a> and  <a class="medical medical_review" href="/z/d/html/5089.html" rel="external">"Cognitive impairment and dementia in Parkinson disease", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H496926329"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83158.html" rel="external">"Patient education: Dementia with Lewy bodies (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/736.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1764720952"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>Dementia with Lewy bodies (DLB), a clinical syndrome characterized by fluctuating cognitive impairment, dysautonomia, sleep disorders, hallucinations, and parkinsonism, is recognized as one of the most common causes of dementia accounting for as much as 30 percent of all dementia cases. (See <a class="local">'Incidence and prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic features</strong> – The pathologic hallmarks are Lewy bodies and Lewy neurites throughout the cortex best identified with the aid of alpha-synuclein immunohistochemistry. (See <a class="local">'Microscopic pathology'</a> above.)</p><p></p><p class="bulletIndent1">Most patients with DLB will have some degree of Alzheimer-type pathology as well. (See <a class="local">'Microscopic pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Aggregated alpha-synuclein is a key component of Lewy bodies and Lewy neurites. Dopaminergic neurons appear to be more susceptible to alpha-synuclein dysfunction. Cholinergic neuronal loss is also demonstrated and may be particularly important in the development of cognitive impairment in DLB. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic and other risk factors</strong> – Although there are relatively few examples of familial DLB and the majority are late-onset, sporadic cases, genetics appear to play an important role in both the pathogenesis and risk of DLB. (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1">Environmental factors have been less well characterized than in Parkinson disease (PD); however, they are presumed to play a role in DLB as well. (See <a class="local">'Acquired risk factors'</a> above.)</p><p></p><p class="headingAnchor" id="H424314129"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Ann Marie Hake, MD, and Martin R Farlow, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44:673.</a></li><li><a class="nounderline abstract_t">Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34:561.</a></li><li><a class="nounderline abstract_t">Wakisaka Y, Furuta A, Tanizaki Y, et al. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 2003; 106:374.</a></li><li><a class="nounderline abstract_t">Barber R, Panikkar A, McKeith IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001; 16 Suppl 1:S12.</a></li><li><a class="nounderline abstract_t">Savica R, Grossardt BR, Bower JH, et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol 2013; 70:1396.</a></li><li><a class="nounderline abstract_t">Latimer CS, Keene CD, Flanagan ME, et al. Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. J Neuropathol Exp Neurol 2017; 76:458.</a></li><li><a class="nounderline abstract_t">Lowe J. Neuropathology of dementia with Lewy bodies. Handb Clin Neurol 2008; 89:321.</a></li><li><a class="nounderline abstract_t">McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89:88.</a></li><li><a class="nounderline abstract_t">McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113.</a></li><li><a class="nounderline abstract_t">Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998; 57:334.</a></li><li><a class="nounderline abstract_t">Lennox G, Lowe J, Landon M, et al. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989; 52:1236.</a></li><li><a class="nounderline abstract_t">Hansen LA, Masliah E, Terry RD, Mirra SS. A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol 1989; 78:194.</a></li><li><a class="nounderline abstract_t">Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008; 115:427.</a></li><li><a class="nounderline abstract_t">Howlett DR, Whitfield D, Johnson M, et al. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. Brain Pathol 2015; 25:401.</a></li><li><a class="nounderline abstract_t">Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 2017; 13:457.</a></li><li><a class="nounderline abstract_t">Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 2006; 65:685.</a></li><li><a class="nounderline abstract_t">Haroutunian V, Serby M, Purohit DP, et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 2000; 57:1145.</a></li><li><a class="nounderline abstract_t">Nelson PT, Kryscio RJ, Jicha GA, et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology 2009; 73:1127.</a></li><li><a class="nounderline abstract_t">Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125:391.</a></li><li><a class="nounderline abstract_t">Benarroch EE, Schmeichel AM, Sandroni P, et al. Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease. Neurology 2006; 66:378.</a></li><li><a class="nounderline abstract_t">Gómez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999; 53:1284.</a></li><li><a class="nounderline abstract_t">Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55:44.</a></li><li><a class="nounderline abstract_t">Benarroch EE, Schmeichel AM, Dugger BN, et al. Dopamine cell loss in the periaqueductal gray in multiple system atrophy and Lewy body dementia. Neurology 2009; 73:106.</a></li><li><a class="nounderline abstract_t">Lemstra AW, de Beer MH, Teunissen CE, et al. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2017; 88:113.</a></li><li><a class="nounderline abstract_t">Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60:1586.</a></li><li><a class="nounderline abstract_t">Lippa CF, McKeith I. Dementia with Lewy bodies: improving diagnostic criteria. Neurology 2003; 60:1571.</a></li><li><a class="nounderline abstract_t">Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102:355.</a></li><li><a class="nounderline abstract_t">Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. J Neural Transm (Vienna) 2018; 125:615.</a></li><li><a class="nounderline abstract_t">Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011; 32:857.</a></li><li><a class="nounderline abstract_t">Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839.</a></li><li><a class="nounderline abstract_t">Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9:13.</a></li><li><a class="nounderline abstract_t">Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197.</a></li><li><a class="nounderline abstract_t">Murray IVJ, Lee VMY, Trojanowski JQ. Synucleinopathies: A pathological and molecular review. Clin Neurosci Res 2001; 1:445.</a></li><li><a class="nounderline abstract_t">Yu S, Uéda K, Chan P. Alpha-synuclein and dopamine metabolism. Mol Neurobiol 2005; 31:243.</a></li><li><a class="nounderline abstract_t">Gao N, Li YH, Li X, et al. Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene. Neurosci Bull 2007; 23:53.</a></li><li><a class="nounderline abstract_t">Butler B, Saha K, Rana T, et al. Dopamine Transporter Activity Is Modulated by α-Synuclein. J Biol Chem 2015; 290:29542.</a></li><li><a class="nounderline abstract_t">Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5:747.</a></li><li><a class="nounderline abstract_t">Perry EK, Marshall E, Perry RH, et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord 1990; 4:87.</a></li><li><a class="nounderline abstract_t">Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000; 48:868.</a></li><li><a class="nounderline abstract_t">Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7:69.</a></li><li><a class="nounderline abstract_t">Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 2009; 1792:730.</a></li><li><a class="nounderline abstract_t">Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11:301.</a></li><li><a class="nounderline abstract_t">Henderson MX, Trojanowski JQ, Lee VM. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Neurosci Lett 2019; 709:134316.</a></li><li><a class="nounderline abstract_t">Hansen C, Angot E, Bergström AL, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121:715.</a></li><li><a class="nounderline abstract_t">Lee HJ, Suk JE, Bae EJ, et al. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008; 40:1835.</a></li><li><a class="nounderline abstract_t">Brundin P, Melki R. Prying into the Prion Hypothesis for Parkinson's Disease. J Neurosci 2017; 37:9808.</a></li><li><a class="nounderline abstract_t">Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14:504.</a></li><li><a class="nounderline abstract_t">Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14:501.</a></li><li><a class="nounderline abstract_t">Magen I, Chesselet MF. Mouse models of cognitive deficits due to alpha-synuclein pathology. J Parkinsons Dis 2011; 1:217.</a></li><li><a class="nounderline abstract_t">Norris EH, Giasson BI, Lee VM. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 2004; 60:17.</a></li><li><a class="nounderline abstract_t">Hatami A, Chesselet MF. Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits. Curr Top Behav Neurosci 2015; 22:303.</a></li><li><a class="nounderline abstract_t">Mahul-Mellier AL, Burtscher J, Maharjan N, et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A 2020; 117:4971.</a></li><li><a class="nounderline abstract_t">Prots I, Grosch J, Brazdis RM, et al. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc Natl Acad Sci U S A 2018; 115:7813.</a></li><li><a class="nounderline abstract_t">Piper DA, Sastre D, Schüle B. Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease. Front Neurosci 2018; 12:199.</a></li><li><a class="nounderline abstract_t">Lee G, Cummings J, Decourt B, et al. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opin Investig Drugs 2019; 28:951.</a></li><li><a class="nounderline abstract_t">Zhang Q, Kim YC, Narayanan NS. Disease-modifying therapeutic directions for Lewy-Body dementias. Front Neurosci 2015; 9:293.</a></li><li><a class="nounderline abstract_t">Guerreiro R, Ross OA, Kun-Rodrigues C, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 2018; 17:64.</a></li><li><a class="nounderline abstract_t">Guerreiro R, Escott-Price V, Hernandez DG, et al. Heritability and genetic variance of dementia with Lewy bodies. Neurobiol Dis 2019; 127:492.</a></li><li><a class="nounderline abstract_t">Orme T, Hernandez D, Ross OA, et al. Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathol Commun 2020; 8:5.</a></li><li><a class="nounderline abstract_t">Orme T, Guerreiro R, Bras J. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions. Curr Neurol Neurosci Rep 2018; 18:67.</a></li><li><a class="nounderline abstract_t">Tolea MI, Galvin JE. The genetics of dementia with Lewy bodies. Handb Clin Neurol 2018; 148:431.</a></li><li><a class="nounderline abstract_t">Ohtake H, Limprasert P, Fan Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004; 63:805.</a></li><li><a class="nounderline abstract_t">Guyant-Marechal I, Berger E, Laquerrière A, et al. Intrafamilial diversity of phenotype associated with app duplication. Neurology 2008; 71:1925.</a></li><li><a class="nounderline abstract_t">Armstrong RA, Lantos PL, Cairns NJ. Overlap between neurodegenerative disorders. Neuropathology 2005; 25:111.</a></li><li><a class="nounderline abstract_t">Rosenberg CK, Pericak-Vance MA, Saunders AM, et al. Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. Acta Neuropathol 2000; 100:145.</a></li><li><a class="nounderline abstract_t">Meeus B, Theuns J, Van Broeckhoven C. The genetics of dementia with Lewy bodies: what are we missing? Arch Neurol 2012; 69:1113.</a></li><li><a class="nounderline abstract_t">Ishikawa A, Piao YS, Miyashita A, et al. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann Neurol 2005; 57:429.</a></li><li><a class="nounderline abstract_t">Kaneko H, Kakita A, Kasuga K, et al. Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease. J Neurosci 2007; 27:13092.</a></li><li><a class="nounderline abstract_t">Colom-Cadena M, Gelpi E, Martí MJ, et al. MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies. Neurobiol Aging 2013; 34:936.</a></li><li><a class="nounderline abstract_t">Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006; 67:908.</a></li><li><a class="nounderline abstract_t">Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008; 65:379.</a></li><li><a class="nounderline abstract_t">Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013; 70:727.</a></li><li><a class="nounderline abstract_t">Gegg ME, Schapira AHV. The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J 2018; 285:3591.</a></li><li><a class="nounderline abstract_t">Clark LN, Kartsaklis LA, Wolf Gilbert R, et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009; 66:578.</a></li><li><a class="nounderline abstract_t">Shiner T, Mirelman A, Gana Weisz M, et al. High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. JAMA Neurol 2016; 73:1448.</a></li><li><a class="nounderline abstract_t">Berge G, Sando SB, Rongve A, et al. Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry 2014; 85:1227.</a></li><li><a class="nounderline abstract_t">Boot BP, Orr CF, Ahlskog JE, et al. Risk factors for dementia with Lewy bodies: a case-control study. Neurology 2013; 81:833.</a></li><li><a class="nounderline abstract_t">Tsuang D, Leverenz JB, Lopez OL, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013; 70:223.</a></li><li><a class="nounderline abstract_t">Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014; 23:6139.</a></li><li><a class="nounderline abstract_t">Gennarini G, Bizzoca A, Picocci S, et al. The role of Gpi-anchored axonal glycoproteins in neural development and neurological disorders. Mol Cell Neurosci 2017; 81:49.</a></li><li><a class="nounderline abstract_t">Gulisano W, Bizzoca A, Gennarini G, et al. Role of the adhesion molecule F3/Contactin in synaptic plasticity and memory. Mol Cell Neurosci 2017; 81:64.</a></li><li><a class="nounderline abstract_t">Wang CS, Burke JR, Steffens DC, et al. Twin pairs discordant for neuropathologically confirmed Lewy body dementia. J Neurol Neurosurg Psychiatry 2009; 80:562.</a></li><li><a class="nounderline abstract_t">Crane PK, Gibbons LE, Dams-O'Connor K, et al. Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol 2016; 73:1062.</a></li></ol></div><div id="topicVersionRevision">Topic 5087 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23521899" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267179" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A systematic review of prevalence and incidence studies of dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904992" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11748785" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dementia with Lewy bodies: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24042491" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of dementia with Lewy bodies and Parkinson disease dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28499012" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18631757" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neuropathology of dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592453" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909416" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600226" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2556498" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2546359" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18273624" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25103200" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28708131" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A clinicopathological approach to the diagnosis of dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825955" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10927794" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805729" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844739" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476936" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522886" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical and quantitative pathologic correlates of dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558171" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597132" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dopamine cell loss in the periaqueductal gray in multiple system atrophy and Lewy body dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27794030" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771246" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771241" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dementia with Lewy bodies: improving diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603811" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cortical Lewy body pathology in the diagnosis of dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222591" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19560232" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9278044" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Alpha-synuclein in Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23183883" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 100 years of Lewy pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12498954" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Staging of brain pathology related to sporadic Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Synucleinopathies: A pathological and molecular review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953825" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Alpha-synuclein and dopamine metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592526" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26442590" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dopamine Transporter Activity Is Modulated byα-Synuclein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018843" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2357341" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cholinergic and dopaminergic activities in senile dementia of Lewy body type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117543" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8347330" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18718530" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308987" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prion-like transmission of protein aggregates in neurodegenerative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31170426" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : α-Synuclein pathology in Parkinson's disease and relatedα-synucleinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245577" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291704" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29021298" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prying into the Prion Hypothesis for Parkinson's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391962" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391963" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939303" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mouse models of cognitive deficits due to alpha-synuclein pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15094295" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Alpha-synuclein: normal function and role in neurodegenerative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25218491" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32075919" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The process of Lewy body formation, rather than simplyα-synuclein fibrillization, is one of the major drivers of neurodegeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29991596" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686602" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31614096" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical drug development for dementia with Lewy bodies: past and present.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347604" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Disease-modifying therapeutic directions for Lewy-Body dementias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29263008" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953760" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Heritability and genetic variance of dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31996268" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097731" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29478592" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The genetics of dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365127" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Beta-synuclein gene alterations in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047566" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Intrafamilial diversity of phenotype associated with app duplication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15875904" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Overlap between neurodegenerative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10963361" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22635379" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The genetics of dementia with Lewy bodies: what are we missing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15732120" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18045903" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22819391" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : MAPT H1 haplotype is associated with enhancedα-synuclein deposition in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790605" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18332251" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588557" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29385658" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The role of glucocerebrosidase in Parkinson disease pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433657" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Association of glucocerebrosidase mutations with dementia with lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27723861" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24639435" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Apolipoprotein Eε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892702" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risk factors for dementia with Lewy bodies: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407718" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : APOEε4 increases risk for dementia in pure synucleinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24973356" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27871938" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The role of Gpi-anchored axonal glycoproteins in neural development and neurological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28038945" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Role of the adhesion molecule F3/Contactin in synaptic plasticity and memory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19372291" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Twin pairs discordant for neuropathologically confirmed Lewy body dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27400367" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
